Celsion Corporation (now identified in the request as Imunon, Inc.) — Q3 2019 Form 10-Q
Reporting period: Three and nine months ended September 30, 2019; filed November 14, 2019. The filing identifies the registrant as Celsion Corporation, ticker CLSN. Financial statements are unaudited.
Business context
Celsion was a clinical-stage oncology company with no material product sales. Its lead candidate, ThermoDox, was in the Phase III OPTIMA trial for primary liver cancer; GEN-1 was being studied for ovarian cancer, with the OVATION 2 trial in Phase I/II. Revenue consisted of deferred licensing revenue under the Hisun agreement.
Financial results and position
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Licensing revenue | $125,000 | $125,000 | $375,000 | $375,000 |
| Research and development | $3.67 million | $2.19 million | $10.00 million | $9.52 million |
| General and administrative | $1.84 million | $1.96 million | $6.19 million | $7.17 million |
| Operating loss | $5.39 million | $4.02 million | $15.82 million | $16.31 million |
| Net loss | $5.48 million | $4.66 million | $13.75 million | $17.36 million |
| Basic and diluted loss per share | $0.25 | $0.26 | $0.67 | $1.00 |
- Q3 R&D expense rose 68%, largely reflecting higher clinical research and manufacturing costs; prior-year OPTIMA expenses benefited from a one-time CRO credit. Nine-month R&D increased 5%, while G&A fell 14%, partly due to lower stock-based compensation.
- Q3 net loss increased year over year; nine-month net loss improved, helped in part by a $3.09 million non-cash gain from revaluing the EGEN earn-out liability. Nine-month results also included a $400,000 non-cash expense for warrants issued in connection with the earn-out amendment. The comparable 2018 periods included a $4.51 million IPR&D impairment charge.
- At September 30, cash and cash equivalents were $8.52 million, available-for-sale investments $10.29 million, and accrued investment interest $27,000—about $18.8 million combined. Current assets were $20.11 million and current liabilities $7.79 million, for working capital of $12.3 million, down from $22.0 million at year-end 2018.
- Operating cash use was $14.64 million for the nine months, compared with $13.13 million in 2018. Investing activities provided $3.64 million, principally reflecting net investment-security maturities and purchases; financing activities provided $6.16 million, primarily from equity sales. Cash decreased $4.83 million to $8.52 million.
- Debt was under the Horizon facility: $10 million original principal, secured by substantially all assets except intellectual property, with interest at one-month LIBOR plus 7.625%. The balance-sheet carrying amount was $9.71 million, net of unamortized costs; $579,000 was classified current. Principal amortization was scheduled to begin after the initial interest-only period.
- No operating margin is meaningful given minimal licensing revenue and the company’s development-stage operations. Accumulated deficit was approximately $287 million.
Material developments, outlook and risks
- Management said existing cash and investments, expected proceeds from New Jersey tax-credit sales, and available equity facilities were expected to fund operations into Q2 2021. This was an estimate dependent on financing availability, clinical and development spending, and other assumptions; the company stated it would need additional funding to continue development. It expected about $2.0 million net proceeds from the 2019 New Jersey NOL program before year-end.
- After quarter-end, the OPTIMA trial’s first planned interim review followed 128 deaths. The independent monitoring committee recommended continuing the study; the company reported blinded data and had not disclosed an unblinded efficacy result. The next planned interim efficacy analysis was projected for Q2 2020, subject to event timing. The filing also reported median PFS of 17 months in blinded OPTIMA data and median OS not yet reached; these observations do not establish efficacy.
- The company completed OPTIMA enrollment at 556 patients in August 2018. Its prior Phase III HEAT study failed its primary progression-free-survival endpoint; the OPTIMA design relies on post-hoc subgroup analyses from HEAT, which carry uncertainty.
- The 2018 Aspire equity purchase agreement was terminated after quarter-end and replaced on October 28, 2019 with a new agreement for up to $10 million over 24 months. Celsion also had $15.2 million remaining under the JonesTrading at-the-market facility at September 30. Use of these facilities could dilute shareholders. Shares outstanding increased to 22.0 million at quarter-end from 18.8 million at year-end 2018.
- The EGEN earn-out liability was $5.82 million at September 30. Under the amended terms, the company may owe $7.0 million cash shortly after achievement of the relevant milestone, or $12.4 million in cash, stock, or a combination within one year. Its valuation relies on significant estimates and probabilities.
- A shareholder derivative and putative class action filed in New Jersey in September alleged improper statements in seeking approval of the 2018 Stock Incentive Plan and sought, among other things, damages and invalidation or disgorgement of plan awards. The filing does not quantify a probable loss.
- Adoption of lease accounting in 2019 added operating lease right-of-use assets and liabilities; the September 30 lease liability was $1.62 million. Management reported disclosure controls effective at a reasonable-assurance level and no material change in internal control over financial reporting, apart from implementation of lease-accounting processes.
- Key risks include continued operating losses, dependence on additional capital, clinical-trial and regulatory failure or delay, reliance on third-party CROs and manufacturers, potential dilution, and uncertainty around commercialization and reimbursement. Management expected losses to continue for the foreseeable future; the filing provided no earnings or revenue guidance.
Important facts for investors to verify
- Latest OPTIMA interim-review status, event timing, and whether subsequent disclosures provide unblinded efficacy results.
- Actual cash runway and subsequent cash receipts, including New Jersey tax-credit proceeds and equity-facility sales.
- Subsequent share issuance, dilution, and remaining availability under the Aspire and JonesTrading facilities.
- Terms, timing, and potential cash or stock impact of any EGEN earn-out milestone payment.
- Developments and potential financial exposure in the shareholder lawsuit.